HIV/AIDS AND THE KNOWLEDGE GAP:

Slides:



Advertisements
Similar presentations
Nick Curry, MD, MPH Infectious Diseases Prevention Section
Advertisements

Title: PEOPLE LIVING WITH HIV/AIDSIN EGYPT: ROLE OF COMMUNITY PHARMACIST Authors: Nahla Maher Hegab Pharmacy graduate. Institution: College of pharmacy,
STD Screening in HIV Clinics: Value and Implications Thomas Farley, MD MPH Tulane University Deborah Cohen, MD MPH RAND Corporation.
Epidemiology of HIV-2 infection in the U.S, Lata Kumar MS, MPH Richard Selik MD Division of HIV/AIDS Prevention National Center for HIV/AIDS,
Health & Medicine n Medical Sociology. Society shapes human health n Cultural patterns define what is or is not healthy n Social inequality n Technology.
Use of epidemiologic methods in disaster management Dr AA Abubakar Dept of Community Medicine Ahmadu Bello University Zaria Nigeria.
Preventing HIV/AIDS There is no way to tell just by looking whether a person is infected with HIV. Because people are unaware that they are HIV-positive,
Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, Al Jouf University.
1 HIV/STD Trends in Texas Sharon K. Melville, M.D., M.P.H. Texas Department of State Health Services Texas Public Health Association April 22, 2010.
The HIV/AIDS Epidemic © 2013 John B. Pryor Illinois State University.
A Webinar Hosted by The National Harm Reduction Coalition The National Black Leadership Commission on AIDS The Coalition for Positive Health Empowerment.
HIV/AIDS Epidemiology Update February 2009 Dr Nigel Dickson Director, AIDS Epidemiology Group Department of Preventive and Social Medicine University of.
Facts About HIV/AIDS What Is HIV? Human Immunodeficiency Virus HIV infects human cells and uses the energy and nutrients provided by those cells to grow.
1 AIDS 2010 Vienna, July 2010 HIV/AIDS and People from Countries where HIV is endemic – Black people of African and Caribbean descent living in Canada.
Chapter 24; Lesson 3.  Human Immunodeficiency Virus (HIV) – a virus that attacks the immune system.  Once HIV enters the body, it finds and destroys.
Track A: Basic Science This track highlighted all aspects of HIV structure, replication, and the host immune responses and led to a greater understanding.
Crisis in Africa: HIV/AIDS. What is HIV\AIDS? HIV- Human Immunodeficiency Virus – HIV attacks the T-cells in the body which are needed to help fight off.
Dutch Dental Students HIV- related attitudes, knowledge & source of information AH. Neshat, K. Divaris, R.C. Gorter, PhD An EDSA project…
Sexually Transmitted Infections Mysheika Williams Roberts, MD, MPH Medical Director Assistant Health Commissioner Columbus.
00002-E-1 – 1 December 2002 The AIDS Pandemic: an Update on the Numbers and Needs l What are the numbers for 2002? l What are the global and regional trends?
Quarterly HIV/AIDS Analysis for Michigan January 1, 2008 Michigan Department of Community Health HIV/STD/Viral Hepatitis and TB Epidemiology Section Division.
1 Counseling and HIV Testing HAIVN Harvard Medical School AIDS Initiatives in Vietnam.
HIV Care Continuum Persons Living With HIV, Georgia, 2012.
Chapter 25 Lessons 3 & 4 Handshake Cards. Teens at Risk Teens have one of the fastest growing rates of HIV infection. Teens have one of the fastest growing.
Introduction to OraQuick Rapid HIV Testing William F. Ryan Community Health Center School Based Health Program.
HIV is the virus that causes AIDS, a disease that weakens the body’s immune system and may have fatal consequences.
The Inflammatory Breast Cancer Cancer Registry Paul H. Levine, M.D. Paul H. Levine, M.D. The George Washington University School of Public Health and Health.
00002-E-1 – 1 December 2001 Global summary of the HIV/AIDS epidemic, December 2001 Number of people living with HIV/AIDS Total40 million Adults37.2 million.
00002-E-1 – 1 December 2002 Global summary of the HIV/AIDS epidemic, December 2002 Number of people living with HIV/AIDS Total42 million Adults38.6 million.
Focus Area 25 Sexually Transmitted Diseases Progress Review July 21, 2004.
Quarterly HIV/AIDS Analysis for Michigan January 1, 2007 Michigan Department of Community Health HIV/STD & Other Bloodborne Infections Surveillance Section.
Herpes Simplex Virus Type 2 infection among U.S. military service members: Public Health Implications and Opportunities for HIV Prevention Christian T.
00002-E-1 – 1 December 2001 THE HIV/AIDS PANDEMIC Focus on Africa By Dr. David Elkins HIV/AIDS Prevention and Care Project Nairobi, Kenya September 2002.
Notified AIDS and HIV Infection Cases in the Seychelles: Epidemiological Trends Ministry of Health, SeychellesMinistry of Health, Seychelles –N. E. Udonwa.
CONCLUSIONS New Jersey’s Emergency Department HIV testing sites report higher seroprevalence than non-ED testing sites. Since University Hospital began.
Thematic Priorities for ATF Applications Presentation by Secretariat of Council for the AIDS Trust Fund in Briefing Session on 27 July
Demographic and Behavioral Differences between Latino and non-Latino Patients Attending Baltimore City STD Clinics, Renee M. Gindi 1, Kathleen.
Update on epidemiology of HIV in New Zealand Dr Sue McAllister AIDS Epidemiology Group (AEG) University of Otago Dunedin HIV Women’s Seminar Auckland,
Health Lesson: Day 3 Chapter 25, Lesson 4: Treatment for HIV and AIDS.
Mortality: Model Life Tables
HIV Infection in Women in Our Community: The Continuum of Care
Lesson 4 Treatment for HIV / AIDS
1University of Kentucky, Lexington, Kentucky
SEXUALLY TRANSMITTED DISEASES
HIV-1 and STIs Prevalence and Risk Factors among Miners and Female Sex Workers in the Mining Areas of Gejiu, Yunnan, China Ding Guowei, M.D., M.S. National.
HIV TESTING IN NEWLY DIAGNOSED LYMPHOMAS IN NOTTINGHAM CITY HOSPITAL
PREVALENCE OF HEPATITIS B VIRUS INFECTION AMONG FEDERAL
Prevalence of HIV infection among blood donors at the National Blood Transfusion Centre in Bangui, Central African Republic Claudine Bekondi1a, Pulchérie.
Introduction Results Conclusions Methods
Relationship between CMV & PU disease
Daffodil International University (DIU), Dhaka Bangladesh
HIV/AIDS in Africa: Could the story have been different in Nigeria?
California Clinical Laboratory Association
High Positivity of Antibodies against HIV Type 1, 2, O and P24
Lesson 4 Treatment for HIV / AIDS
وضعیت HIV/AIDS در جهان ومنطقه مرکز مدیریت بیماری ها - اداره كنترل ایدز و بیماری های آمیزشی
CDC Guidelines for Use of QuantiFERON®-TB Gold Test
PHARMACOTHERAPY III PHCY 510
11/20/2018 Study Types.
HIV/ AIDS.
Frequency and implications of HIV superinfection
Needs Assessment Slides for Module 4
Summary Sheet Figures and Maps
Introduction to Epidemiology
HIV Testing in the U. S. Julie Saber Galen College of Nursing
HIV Recency Testing in Rwanda
MSM Attending STD Clinics HIV Testing More Frequently: Implications for HIV Prevention and Surveillance D Helms1, H Weinstock1, K Mahle1, A Shahkolahi1,2,
HIV/AIDS In Botswana.
Public Health Implications
Presentation transcript:

HIV/AIDS AND THE KNOWLEDGE GAP: FAILURE OF PRE-PANDEMIC RESEARCH TO AVERT DISASTER IN PARTS OF AFRICA Christopher K. Williams College of Medicine, University of Ibadan, and University College Hospital, Ibadan, Nigeria, Nanaimo General Hospital, and University of British Columbia, Nanaimo and Vancouver, BC, Canada

Abstract 504 The current high seroprevalence rate (SPR) for HIV in Subsaharan Africa stands in striking contrast with the low rates, even in individuals of high-risk lifestyle, observed in surveys of pre-pandemic period in certain locales. Human retroviral research in Nigeria dates back to 1983 with the description of the index case of adult T-cell leukaemia/lymphoma. Subsequent screening of normal blood donors, school children and patients with haematological disorders with first-generation ELISA and lymphocyte immunophenotyping techniques revealed HTLV-I SPR of 6.4%, 0.0% and 0.0%-13% respectively, as well as unexplained fatal cases of immunodeficiency and lymphadenopathy/dermatitis. A WHO sponsored survey of risk factors of retroviral infection carried out in parts of Nigeria from 1985 to 1986 involved assessment of lifestyle of members of 5 population groups by a detailed questionnaire. They included 237 normal blood donors (NBD), 46 female commercial sex workers (FCSW), 54 male-, 17 female celibates (MC/FC) and 42 sexually transmitted diseases (STD) clinic patients (STDCP), who were screened for HTLVs and HIVs by ELISA and Western blot (WB). HTLV-I SPR for NBD, FCSW, MC, FC and STDCP were 4.6%, 13%, 16.7%, 1.85% and 11.8%. Multivariate analysis revealed eastern Nigerian origin (ENO) (p=0.0000095), female sex (p=0.037) and female sex of ENO (p=0.0006) but not ethnicity (p=0.215) or polygamy (p=0.43) as risk factors for HTLV-I infection. Confirmation of HIV-1/2 SPR in the study group was not possible until the development in the 1990's of the recombinant enhanced "Singapore" HIV-1/2 WB, which identified 2 HIV-1, but 0 HIV-2 cases, thus yielding HIV-1 SPR of 0% for FCSW, MC, FC, STDCP, and ≈0.5%-1.0% in NBD nationally. Retrospective estimates indicates expected ≈2400-4800 AIDS deaths in 1985/6 at the University College Hospital, the main health care unit of the region, ≈5 of which were clinically diagnosed. In addition to the educational challenges resulting in the knowledge gap (vis-à-vis the situation in developed countries) about HIV/AIDS, cultural and infrastructural challenges probably also contributed to the failure of averting the disastrous progression of the pandemic in areas where timely intervention might have been effective. Senegal was another locale where retroviral research program was in place prior to the HIV/AIDS crisis. The low Senegalese HIV SPR probably resulted from early recognition of the dangers of the new disease and the prevailing cultural millieu, in contrast to other West African locales. Recent Ugandan experiences indicate that a reversal of the pandemic is possible in Subsaharan Africa. Lessons learnt from failure to control HIV/AIDS could help in confronting emerging new health challenges, including AIDS associated malignancies, breast and lung cancer as well as other diseases of "westernization" and changing lifestyles in Africa.

HTLV- I INFECTION IN NIGERIA – THE INDEX CASE The picture of a 19-year old Nigerian boy whom we studied 10 years and diagnosed as having ATL. He was the first of the disease to be observed in an African. We were able to show that he had clinical and laboratory features of ATL and had antibodies to HTLV-I. We subsequently initiated a series of studies in collaboration with Dr Gallo's lab. at the NCI in Bethesda, MD, as well as with the NCI's Viral Epidemiology Section through its Chief, Dr W A Blattner. Describe SLIDE 13: In analysing the results of the K study, we observed that HTLV-I seropositivity occured in all 4 patients who were diagnosed to have ATL on clinical grounds. Lower seroprevalence rates were observed in other hematologic malignancies. Seroprevalence rates in healthy adult blood donors and school children were 11% and 21% respectively (but with very wide 95% confidence intervals). We concluded that HTLV-I was endemic in Nigeria at about the same seroprevalence rates as in Japan and the West Indies, but that the frequency of ATL was unexplainably lower in Nigerians compared to the other endemic areas. 19-yr old Nigerian with ATL diagnosed in early 1980’s, believed to be the first such patient to be appropriately documented on the African continent

23 yr old Nigerian woman with features of AIDS, 1983 (case 2)    

Survey of Risk Factors For Retroviral Infection in Nigerians sponsored by the World Health Organization; Purpose of the study: To evaluate the role of sexual behavior in the transmission of human retroviruses among Nigerians Methods: enzyme-linked immunoabsorbent assay (ELISA) and an investigational Western blot, A small survey of the seroprevalence of HTLV-I and HIV was conducted in 1985/86 sponsored by the World Health Organization; Purpose of the study: To evaluate the role of sexual behavior in the transmission of human retroviruses among Nigerians Methods: Using enzyme-linked immunoabsorbent assay (ELISA) and an investigational Western blot, a small survey of the seroprevalence of HTLV-I and HIV was conducted in 1985/86 among 5 population groups with differing lifestyles and sexual behavior as assessed by a detailed questionnaire . They included normal blood donors, female prostitutes, patients attending a sexually transmitted diseases (STD) clinic, and young men and women who were required to be celibate for religious reasons.

5 population groups with differing lifestyles and sexual behavior as assessed by a detailed questionnaire Normal blood donors; female commercial sex workers; patients attending a sexually transmitted diseases (STD clinic); Seminarians and Nuns (celibate for religious reasons).

Dear Chris - Among 204 subjects in the HIV database under our study code WLL (Williams), we found two subjects (# 200042 and 105780) who were scored as positive for HIV-1 (negative for HIV-2) with a recombinant enhanced "Singapore" HIV-1/2 Western blot. All of the HIV serology data for these two subjects are in the attached Word file. Subject 200042 was very weakly reactive in only one EIA; subject 105780 was weakly reactive in two EIAs. I could get the specific Western blot band patterns if you like, but I can predict that they had at least three bands, all of which were weak but discernable (which we score as a minimum density of 2 on an 11-point scale from pure white to pure black). The blots were done in August 1994.

WHO Survey: HIV- I Seroprevalence 1985 - 1986 SSTUDY=WLL STUDY NAME=WILLIAMS - HTLV/NIGERIA,U OF IB SUBJECT SAMPLE VIRUS TEST ID ID TYPE ASSAY RESULT DATE -------------------------------------------------------------------------------------------------------------------- 200042 L 9191 HIV-1 ANTI P24 - 0.00 31OCT88 HIV-1 ANTI 120 - 0.00 31OCT88 HIV-1 ENI WV - 1.84 31OCT88 HIV-1 GEN EIA - 1.10 15DEC94 HIV-1 GN PEP E - 1.00 15DEC94 HIV-2 GEN EIA + 1.30 06JAN88 HIV-2 GEN EIA - 1.10 15DEC94 HIV-2 GN PEP E - 1.00 15DEC94 HIVI&II SNG BLOT +,0 29AUG94 105780 L 9289 HIV-1 ANTI P24 - 0.00 31OCT88 HIV-1 ANTI 120 - 0.01 31OCT88 HIV-1 ENI WV - 0.94 31OCT88 HIV-1 GEN EIA + 3.00 15DEC94 HIV-1 GN PEP E - 1.00 15DEC94 HIV-2 GEN EIA + 1.80 06JAN88 HIV-2 GEN EIA - 1.20 15DEC94 HIV-2 GN PEP E - 1.00 15DEC94 HIVI&II SNG BLOT +,0 25AUG94

HIV SEROPREVALENCE IN NIGERIA 1985 – 1986 only 202 of 394 samples collected from various parts of Nigeria re-studied in 1994 for HIV seropositivity; 2/202 (1.0%) seropositive; The two confirmed cases represented: 1/100 (1%) Ibadan blood donors; 1/53 (1.9%) GOPD patients in Calabar; 1/184 (0.54%) Ibadan+Zaria blood donors; 2/237 (0.84%) Nigerians of no known high-risk sexual behavior; Estimated Seroprevalence Rate: ~0.5%-1%

~12,000-24,000 AIDS deaths in Nigeria in 1985 -1986 Population of adult Nigerians in the period: about 48 million ~240,000 -480,000 HIV seropositive adult Nigerians in 1985-1986; Assuming that the estimate of 1 AIDS death for every 20 HIV seropositive cases, there could have been ~12,000-24,000 AIDS deaths in Nigeria in 1985 -1986

Reasons for detection failure: UCH, Nigeria’s pre-eminent medical facility, had a catchment population of at least 20% of Nigeria (20 million) in 1985-1986; expected AIDS deaths: 2,400-4,800 observed cases with clinical features of AIDS: ~ 5. Reasons for detection failure: technological and infrastructure underdevelopment; ineffective surveillance.

Conclusion Knowledge gap and cultural missteps probably contributed to failure of early control of HIV/AIDS in parts of Africa Lessons learnt from the disaster could help in confronting emerging health challenges, including cancers (breast, lung etc) and other diseases of changing lifestyles in Africa.